fig1
![Molecular mechanisms of enzalutamide resistance in prostate cancer](https://image.oaes.cc/7b6430d6-40f8-4f4b-a110-5aa2af7d864c/3092.fig.1.jpg)
Figure 1. Model of androgen receptor (AR)-dependent and AR-independent mechanisms that enable a castration-resistant prostate cancer (CRPC) to become an enzalutamide resistant-CRPC. EMT: epithelial-mesenchymal transition; GR: glucocorticoid receptor; 1C: one-carbon; NEPC: neuroendocrine prostate cancer